Skip to Content
Merck
All Photos(1)

Key Documents

194824

Sigma-Aldrich

Borane dimethyl sulfide complex solution

2.0 M in toluene

Synonym(s):

BMS, Trihydro[thiobis[methane]]boron

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
(CH3)2S · BH3
CAS Number:
Molecular Weight:
75.97
Beilstein:
3663489
MDL number:
UNSPSC Code:
12352112
PubChem Substance ID:

reaction suitability

reagent type: reductant

concentration

2.0 M in toluene

density

0.856 g/mL at 25 °C

SMILES string

B.CSC

InChI

1S/C2H6S.BH3/c1-3-2;/h1-2H3;1H3

InChI key

RMHDLBZYPISZOI-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Reactant used as a regioselective reducing agent

Reactant involved in:
  • Hydroboration / oxidation
Synthesis of cage compounds

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Oral - Aquatic Chronic 3 - Asp. Tox. 1 - Eye Dam. 1 - Flam. Liq. 2 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 - STOT SE 3 - Water-react 1

Target Organs

Central nervous system

Supplementary Hazards

Storage Class Code

4.3 - Hazardous materials which set free flammable gases upon contact with water

WGK

WGK 3

Flash Point(F)

44.6 °F - closed cup

Flash Point(C)

7 °C - closed cup

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marieke M ter Wee et al.
Annals of the rheumatic diseases, 74(6), 1233-1240 (2014-05-14)
Recently, we documented the likely non-inferiority of Combinatietherapie Bij Reumatoïde Artritis (COBRA)-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day) compared with the original COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with
D J Hunter et al.
Osteoarthritis and cartilage, 23(5), 732-746 (2015-05-09)
Tremendous advances have occurred in our understanding of the pathogenesis of hand osteoarthritis (OA) and these are beginning to be applied to trials targeted at modification of the disease course. The purpose of this expert opinion, consensus driven exercise is
John M Kane et al.
The Journal of clinical psychiatry, 76(3), 240-246 (2015-04-02)
The premise of the National Institute of Mental Health Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE-ETP) is to combine state-of-the-art pharmacologic and psychosocial treatments delivered by a well-trained, multidisciplinary team in order to significantly improve the functional
Pei-Chun Chen et al.
PloS one, 10(4), e0125257-e0125257 (2015-04-30)
Data on the use of oral anticoagulation (OAC) and antiplatelet therapy and the risk of bleeding and stroke amongst Asian patients with atrial fibrillation (AF) are limited. We investigated the risks of bleeding and stroke with use of oral anticoagulation
A Burchert et al.
Leukemia, 29(6), 1331-1335 (2015-02-26)
A minority of chronic myeloid leukemia (CML) patients is capable of successfully discontinuing imatinib. Treatment modalities to increase this proportion are currently unknown. Here, we assessed the role of interferon alpha 2a (IFN) on therapy discontinuation in a previously reported

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service